Glucagon Like Peptide 1 Analogs Market

1
Global Glucagon Like Peptide 1 Analogs Market Is
Estimated To Witness High Growth Owing To
Increasing Prevalence of Diabetes and Growing
Demand for Innovative Therapies The global
Glucagon Like Peptide 1 Analogs Market is
estimated to be valued at US12.55 billion in
2021 and is expected to exhibit a CAGR of 6.10
over the forecast period. This projection has
been highlighted in a new report published by
Coherent Market Insights. A) Market Overview
The Glucagon Like Peptide 1 Analogs Market is a
growing sector in the pharmaceutical industry.
Glp-1 analogs are synthetic drugs that mimic the
action of Glp-1, a hormone secreted by the
intestines that helps regulate blood sugar
levels. These drugs are primarily used for the
treatment of type 2 diabetes and have been found
to be effective in lowering blood sugar levels,
promoting weight loss, and reducing the risk of
cardiovascular events. Examples of Glp-1 analogs
include exenatide and liraglutide, which are
administered through injections. B) Market
Dynamics The Glucagon Like Peptide 1 Analogs
Market is driven by two key factors. Firstly, the
increasing prevalence of diabetes worldwide is
fueling the demand for effective treatment
options. According to the International Diabetes
Federation, around 463 million adults were living
with diabetes in 2019, and this number is
expected to reach 700 million by 2045. Glp-1
analogs offer a promising solution for managing
diabetes and improving patients' quality of
life. Secondly, there is a growing demand for
innovative therapies in the market. Glp-1 analogs
have demonstrated superior efficacy compared to
traditional oral medications used for diabetes
treatment. They not only lower blood sugar
levels but also have additional benefits such as
weight loss, cardiovascular risk reduction, and
improved glycemic control. These advantages have
resulted in increased adoption of Glp-1 analogs
among physicians and patients. C) Market Key
Trends One key trend in the Glucagon Like
Peptide 1 Analogs Market is the development of
once-weekly formulations. Traditional Glp-1
analogs require daily injections, which can be
burdensome for patients. To address this issue,
pharmaceutical companies are developing
long-acting formulations that only need to be
administered on a weekly basis. For example,
Trulicity (dulaglutide) and Ozempic (semaglutide)
are once-weekly Glp-1 analogs that have gained
popularity due to their convenience and improved
patient compliance. D) SWOT Analysis
Strengths 1. Efficacy in managing diabetes.
2. Additional benefits such as weight loss and
cardiovascular risk reduction.
2
Weaknesses 1. Need for injections, which may
be challenging for some patients. 2. High cost
compared to traditional oral medications.
Opportunities 1. Increasing focus on diabetes
management and prevention. 2. Growing demand for
convenient treatment options. Threats 1.
Competition from other diabetes treatment
options. 2. Stringent regulatory requirements
for drug approval. E) Key Takeaways 1. The
global Glucagon Like Peptide 1 Analogs Market is
expected to witness high growth, exhibiting a
CAGR of 6.10 over the forecast period, due to
increasing prevalence of diabetes and the
growing demand for innovative therapies that
offer multiple benefits in diabetes management.
2. The North America region dominates the
Glucagon Like Peptide 1 Analogs Market due to the
high prevalence of diabetes and well-established
healthcare infrastructure. However, the
Asia-Pacific region is expected to witness the
fastest growth in the market, driven by the
rising diabetic population and increasing
healthcare expenditure. 3. Key players operating
in the global Glucagon Like Peptide 1 Analogs
Market include Sun Pharmaceuticals Industries
Ltd, Bristol-Myers Squibb Company, AstraZeneca,
F. Hoffmann-La Roche Ltd.